Lopinavir/ritonavir (Kaletra) — Competitive Intelligence Brief

Lopinavir/ritonavir (Kaletra) (Lopinavir/ritonavir (Kaletra)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

marketed HIV protease inhibitor HIV protease Infectious Disease Small molecule

Target snapshot

Lopinavir/ritonavir (Kaletra) (Lopinavir/ritonavir (Kaletra)) — Abbott. Lopinavir and ritonavir are protease inhibitors that block HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lopinavir/ritonavir (Kaletra) TARGET	Lopinavir/ritonavir (Kaletra)	Abbott	marketed	HIV protease inhibitor	HIV protease
tenofovir + emtricitabine + atazanavir-ritonavir	tenofovir + emtricitabine + atazanavir-ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + PI/r)	HIV reverse transcriptase, HIV protease
Combivir+Kaletra	Combivir+Kaletra	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + protease inhibitor)	HIV reverse transcriptase and HIV protease
Continue Ritonavir-boosted PI+Rosuvastatin	Continue Ritonavir-boosted PI+Rosuvastatin	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + statin)	HIV protease (PI component); HMG-CoA reductase (rosuvastatin component)
lopinavir with ritonavir in 1:1 ratio	lopinavir with ritonavir in 1:1 ratio	Drugs for Neglected Diseases	marketed	HIV protease inhibitor	HIV protease
lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	University of British Columbia	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Lopinavir/ritonavir simplification strategy	Lopinavir/ritonavir simplification strategy	Fundación Huésped	marketed	Protease inhibitor combination	HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

1. Bristol-Myers Squibb · 5 drugs in this class
2. ViiV Healthcare · 3 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Drugs for Neglected Diseases · 2 drugs in this class
5. Germans Trias i Pujol Hospital · 2 drugs in this class
6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
7. DualityBio Inc. · 1 drug in this class
8. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
9. Far East Bio-Tec Co., Ltd · 1 drug in this class
10. Community Research Initiative of New England · 1 drug in this class